<DOC>
	<DOCNO>NCT00462475</DOCNO>
	<brief_summary>Adult patient hypopituitarism adequate conventional hormone replacement therapy reduce life expectancy due excess vascular event ( 1-4 ) . Deficiency GH secretion ( GHD ) likely play major role determine excess mortality , since associate lipid abnormality , visceral adiposity , glucose intolerance , insulin resistance , hypertension , cardiac abnormality increase intima-media thickness ( IMT ) major artery ( 5 ) . Beneficial effect growth hormone ( GH ) replacement cardiovascular risk factor demonstrate several study hypopituitary GHD patient ( 5 ) . GH replacement improve body composition lipid profile ( 5 ) : accept management dyslipidaemia crucial primary secondary prevention cardiovascular disease part excess vascular risk associate hypopituitarism likely due dyslipidaemia ( 6 ) . A meta-analysis blind , randomize , placebo-controlled trial low dos long-duration GH treatment show GH replacement beneficial effect cardiovascular risk improve lean fat body mass , total LDL cholesterol level , diastolic blood pressure ( 7 ) . Besides , GH replacement also induce improvement cardiovascular marker ( 8 ) , cardiac performance ( 9 ) . In small cohort GHD adult , beneficial effect GH replacement 6-24 mo also report surrogate parameter atherosclerosis , intima-media thickness ( IMT ) major artery ( 10-13 ) , 6 month GH deprivation associate impairment cardiovascular risk profile ( 12 ) . In consistent series men woman hypopituitarism report , however , two year GH replacement adequate normalize IMT level common carotid artery ( 13 ) . To give insight likelihood reversal early atherosclerosis severe GHD patient prolong GH replacement , design 5-yr prospective , control study . Only men age ≤50 yr severe GHD enrol avoid gender age interference ( 13 ) . Main outcome measure IMT common carotid artery ; secondary measure prevalence insulin-resistance syndrome accord American College Endocrinology ( 14 ) .</brief_summary>
	<brief_title>Effect 5 Years GH Replacement Atherosclerosis</brief_title>
	<detailed_description>This observational,5-yr prospective , control study . At study entry , subject underwent serum assay IGF-I , systolic diastolic blood pressure ( SBP , DBP ) measurement , total- , HDL-cholesterol , triglyceride , glucose , insulin level overnight fasting , common carotid artery ultrasonography . The oral glucose load ( oGTT ) perform measure blood glucose every 30 minute 2 hour oral administration 75 g glucose dilute 250 ml saline solution . The conversion factor ( mg/dl mmol/l ) lipid glucose follow : cholesterol 0.02586 , triglyceride 0.01129 , glucose 0.05551 . According previous study ( 13,19-21 ) blood pressure measure right arm , subject relaxed sit position . The average six measurement ( three take two examiner , day , 8.00-9.00 morning ) mercury sphygmomanometer use analysis . In patient , parameter carotid ultrasonography re-evaluated 12 , 24 , 36 , 48 60 month control re-evaluated 60 month . At study entry study end , patient control prevalence insulin-resistance syndrome ( IRS ) evaluate accord American College Endocrinology ( 14 ) base presence least two criterion follow : triglyceride level ≥1.7 mmol/liter , HDL-cholesterol level ≤1.0 mmol/liter , blood pressure 130/85 mmHg , fast glucose 6.1 7 mmol/liter 2 hr oGTT 7.7 11.1 mmol/liter .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Pituitary Neoplasms</mesh_term>
	<mesh_term>Hypopituitarism</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>male gender age &lt; 50 yrs limit effect age ; body mass index &lt; 30 Kg/m2 ; familial personal history cardiovascular disease ; concomitant treatment drug know interfere glucose lipid metabolism influence blood pressure time study entry ; previous GH treatment female gender age &gt; 50 yr ; body mass index ≥30 ; familial personal history cardiovascular disease ; previous present treatment drug know interfere glucose lipid metabolism influence blood pressure ; previous GH treatment adult age GHD childhood onset GHD due previous Cushing 's disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>GH</keyword>
	<keyword>IGF-I</keyword>
	<keyword>GH deficiency</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Insulin resistance syndrome</keyword>
</DOC>